I am looking for help identifying all the various constraints, limitations or difficulties in discovery, pre-clinical and clinical pharmacology. Here are some examples we are working to eliminate or limit:
Inconsistent biologics (cell lines, animal lines, reagents etc.)
Failure rates in results duplication
Various biases, design, interpretation
Open source vs. closed source data
Acceptable methods to open up communication and collaboration
We have no doubt you have others. Can you help a small group next to Stanford find a way to move research forward faster while preserving individual and corporate credit and rights? Any suggestions?